Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Domestic ...

Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales. Here’s a breakdown of recent ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Biogen Inc. closed 47.73% short of its 52-week high of $238.00, which the company reached on July 12th.

I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Despite representing great value from an ...